Replies to post #177979 on Biotech Values

[kiroset]

I spent at little time this morning looking at the TGTX story -

For the most part I like what I see

CD20 (TG-1101) is going to be competitive with rituxin coming off patent soon, but I believe the glyco-engineered story as providing a significant improvement. These improved Abs will be used in some fashion - unless combos with generic rituxin cure everyone.

PI3K-delta (TGR-1202) is probably more interesting.

I wish I had more insight into the deal with Rhizen Pharmaceuticals - some more concrete numbers on how much of 1202 that they own, under different possible circumstances.
http://ir.tgtherapeutics.com/releasedetail.cfm?ReleaseID=700800

Since this press release, have they given any more detail on the arrangement?

With one or more phaseIII's on the horizon, they will need to raise money or make a deal in the not too distant future, but hopefully they can roll out some nice results before that is necessary.

With two clearly functional assets against validated targets, this is an easy acquisition target - especially at the current market cap. Reminds me a bit of the YM BioSciences story - despite some management credibility issues, bought by Gilead for $510M for their molecule competitive to Incyte's Jakafi.

[DewDiligence]

Congrats on the nice partial recovery of MNTA today!

I don’t deserve congratulations with respect to MNTA yet. Although I made a sizable purchase last week that was (apparently) close to the bottom (#msg-101624530), those shares aren’t going to show a meaningful profit unless the FDA approves generic Copaxone in a timely manner.

Regarding my prior gains on MNTA from holdings bought in 2007 and sold in 2013, I think in hindsight that I was more lucky than smart. Regards, Dew